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Mutations Disrupting Selenocysteine Formation
Cause Progressive Cerebello-Cerebral Atrophy
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The essential micronutrient selenium is found in proteins as selenocysteine (Sec), the only genetically encoded amino acid whose
biosynthesis occurs on its cognate tRNA in humans. In the final step of selenocysteine formation, the essential enzyme SepSecS catalyzes
the conversion of Sep-tRNA to Sec-tRNA.We demonstrate that SepSecSmutations cause autosomal-recessive progressive cerebellocerebral
atrophy (PCCA) in Jews of Iraqi and Moroccan ancestry. Both founder mutations, common in these two populations, disrupt the sole
route to the biosynthesis of the 21st amino acid, Sec, and thus to the generation of selenoproteins in humans.Progressive cerebellocerebral atrophy (PCCA) is a newly
described autosomal-recessive phenotype of nondysmor-
phic profound mental retardation, progressive micro-
cephaly, and severe spasticity.1 Myoclonic or generalized
tonic-clonic seizures are often observed as well. Repeat
magnetic resonance imaging of affected individuals
showed progressive cerebellar atrophy followed by cerebral
atrophy involving both white and gray matter (Figure 1).
The PCCA phenotype was identified in nonconsanguine-
ous Jewish Sephardic families; parents of affected individ-
uals were either both of Moroccan ancestry, both of Iraqi
ancestry, or of mixed Iraqi-Moroccan ancestry.1
DNA samples of all members of two affected nonconsan-
guineous families of Iraqi ancestry and of two affected
families of mixed Moroccan-Iraqi ancestry were available
for molecular analysis. Samples were obtained after in-
formed consent was secured under approval of the Soroka
Medical Center institutional review board. DNA was
isolated from whole blood of affected individuals with
the FlexiGene DNA Extraction Kit (QIAGEN) per the
manufacturer’s instructions. Lymphoblast cell lines were
established by Epstein-Barr virus (EBV) transformation
via standard methods.
A genome-wide scan of nine individuals of families A
and B and two affected individuals of families C and D
(Figure 2) was done with the GeneChip Human Mapping
10K Array Xba 142 2.0 (Affymetrix) according to the
manufacturer’s guidelines. Detailed mapping of the
PCCA locus was performed with microsatellite markers
selected from public genome databases (Marshfield, Ge´ne´-
ton, and deCODE genetic maps). No likely disease-associ-
ated locus shared by all the affected individuals was
identified.
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the same gene, could be different. Analysis of the two
Iraqi families (Figure 2, families A and B) found that
a single ~8.0 cM locus of homozygosity spanning 18
SNPs between rs1396669 and rs2036184 on chromosome
4p15.2 was shared by the two affected individuals (family
A individual 4 and family B individual 5). Fine mapping of
that locus was done with microsatellite markers. Three
novel microsatellite markers, ch4_AC, ch4_AT, and
ch4_AC2 (Figure 2), were designed with the TANDEM
REPEATS FINDER program, the UCSC Human genome
database, and the PRIMER3 program. Haplotypes were
manually reconstructed and presented graphically with
HaploPainter.2 As shown in Figure 2, fine mapping nar-
rowed the locus to an approximately 4.0 Mb interval of
7.5 cM that was between markers D4S425 and D4S391
and encompassed 15 genes (see Table S1). Interestingly,
at this locus the two affected individuals of mixed Iraqi-
Moroccan ancestry (Figure 2: family C individual 4 and
family D individual 5) shared one haplotype, inherited
from their Iraqi parent, that was identical to that found
in the ‘‘pure’’ Iraqi patients. These two individuals shared
also an approximately 1.4 Mb haplotype between markers
D4S1551 and rs2048506. This haplotype was inherited
from their parent of Moroccan origin and harbored 10
of the 15 genes.
Prioritization of genes from within the defined locus was
done with our Syndrome to Gene (S2G) software.3 S2G
includes a clinical component that is a revised version of
OMIM, and it eliminates negation phrases and integrates
overlapping terminology of phenotyes. S2G also contains
a molecular component, integrating 16 databases of
protein-protein interactions, biochemical pathways, tran-
scription-factor networks, etc. For any syndrome, the soft-
ware selects a prioritized list of candidate genes on the basisnology in the Negev, Ben Gurion University, Beer-Sheva, Israel; 2Pediatric
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Figure 1. Sequential MRI Studies in PCCA
Images are of individual 4 of family A (Figure 2).
(A) Age 8 months: a T1 coronal image at the level of the occipital lobes demonstrates a normal-looking brain.
(B) Age 18 months: a T1 sagital image showing vermian atrophy with mild cerebral atrophy.
(C) Age 3 years: a coronal image at the level of the occipital lobes demonstrates severe cerebellar and cerebral atrophy.of their known molecular interactions with genes associ-
ated with phenotypically similar syndromes. The clinical
presentation of the PCCA patients is most similar to that
of ponto-cerebellar hypoplasia type 2 (PCH2A [MIM
277470], PCH2B [MIM 612389], and PCH2C [MIM
612390]), known to be caused by mutations in the
following genes involved in tRNA processing: TSEN54
(MIM 608755), TSEN2 (MIM 608753), and TSEN34 (MIM
608754), which encode subunits of the tRNA-splicing
endonuclease complex.4 On that basis, S2G suggested
one of the 15 genes in the ~4.0 Mb region as the top candi-
date: SepSecS, encoding O-phosphoseryl-tRNA:selenocys-
teinyl-tRNA synthase, active in catalyzing the conversion
of O-phosphoseryl-tRNA (Sep-tRNA) to Sec-tRNA during
the final step of selenocysteine formation.5,6
Testing samples of affected individuals, we sequenced
SepSecS as well as the other 14 genes in the above locus.
Primer pairs for cDNA and/or each exon including flank-
ing intron sequences of the 15 genes in the putative
4p15.2 locus were designed from cDNA and genomic
sequences via Primer 3. RNA was extracted from cultured
cells of EBV-transformed lymphoblastoid cell lines with
the RNeasy Mini Kit (QIAGEN), and cDNA was reverse
transcribed by the Reverse-iT kit (ABgene) according to
the manufacturer’s protocol. Primer sequences and PCR
conditions are available upon request. PCR products
were directly sequenced with ABI PRISM 3730 DNA
Analyzer according to the protocols of the manufacturer
(Applied Biosystems, Foster City, CA). Sequencing of the
entire coding region and intron-exon borders of SepSecS
identified homozygosity for a missense mutation,
c.1001A>G (NM_016955.3), in both unrelated affected
individuals of Jewish Iraqi ancestry (Figure 3). This muta-
tion leads to substitution of the conserved tyrosine 334
residue with cysteine (p.Tyr334Cys, Figure 4) in the Sep-
SecS protein.The AmericSequencing the entire coding region and intron-exon
borders of all other 14 genes within the 4p15.2 locus iden-
tified no further mutations in those individuals (data not
shown). In the two unrelated affected individuals of mixed
Iraqi-Moroccan origin (Figure 2A, families C and D),
sequencing of SepSecS identified compound heterozygosity
for the c.1001A>G mutation and for another missense
mutation (c.715G>A) in the second (‘‘Moroccan’’) allele
(Figure 3). At the protein level, the c.715G>A mutation
results in replacement of the conserved alanine 239 residue
by threonine (p.Ala239Thr, Figure 4). Interestingly, in two
other nonrelated PCCA families in which both parents
were of Jewish Moroccan ancestry, there were no SepSecS
mutations or homozygosity at the SepSecS locus (data not
shown), suggesting genetic heterogeneity of the pheno-
type.
We went on to test the frequency of carriers of the Sep-
SecSmutations in the normal population: to create a restric-
tion site that would enable easy analysis of the c.1001A>G
mutation, we designed PCR primers in which the 50-to-30
(forward) primer bordered the mutation site and included
one nucleotide change so that the c.1001A>G mutation
would create a FokI restriction site. Using this primer set
for amplification from genomic DNA gave a 151 bp frag-
ment and generated FokI differential cleavage products of
the mutant (121 bp and 30 bp) versus the wild-type
(151 bp). For PCR amplification primers, see Table S2.
We analyzed the c.715G>Amutation by restriction anal-
ysis of SepSecS exon 6 with the restriction enzyme BsrI. The
c.715G>A mutation abolishes a recognition site for BsrI
and generates differential cleavage products of the wild-
type (213 bp and 182 bp) versus mutant (395 bp) alleles
amplified from genomic DNA (Table S2). Of 261 unrelated
healthy Jewish Moroccan individuals, six were found to be
carriers of the ‘‘Moroccan’’ mutation. Of 127 unrelated
healthy Jewish Iraqi individuals, three were carriers ofan Journal of Human Genetics 87, 538–544, October 8, 2010 539
Figure 2. Genetic Mapping of the Disease-Associated Locus
Haplotypes of all four families on chromosome 4p15.2 are shown. The disease-associated haplotype is boxed. Additional microsatellite
markers were used for fine mapping the candidate region identified by the genome-wide scan with the 10K SNP arrays. Families A and B
are of Iraqi origin. Families C and D are of Iraqi and Moroccan origin. The minimum disease-associated haplotype lies between markers
D4S425 and D4S391 for the ‘‘Iraqi’’ haplotype and between markers D4S1551 and rs2048506 for the ‘‘Moroccan’’ haplotype. Gray
shading indicates the SepSecS position within the haplotype.the ‘‘Iraqi’’ mutation. The ‘‘Moroccan’’ mutation was not
found in any of the 127 Iraqi controls, and the ‘‘Iraqi’’
mutation was not found in any of the 261 Moroccan
controls. None of the mutations was found in 192 healthy
Ashkenazi Jewish controls, and no homozygous mutants
were found in any of the normal controls.
The two mutations abrogate SepSecS activity in vivo in
an anaerobic assay that has been readily used in the past
for the characterization of archaeal,5,7 human,5,6 and try-
panosomal8 SepSecS proteins (Figures 5 and 6). In this
system, both p.Ala239Thr and p.Tyr334Cys SepSecS
mutants could not complement an Escherichia coli strain
that lacks its endogenous selenocysteine synthase (SelA)
activity (Figures 5 and 6). Further details are as follows:
the human SepSecS mutants (p.Lys284Thr, p.Ala239Thr,
and p.Tyr334Cys) were generated with the QuikChange
site-directed mutagenesis kit (Stratagene) and cloned into
the pET15b vector with an N-terminal His tag. Construc-540 The American Journal of Human Genetics 87, 538–544, Octobertion of the E. coli DselA deletion strain (DE3) and cloning
of the M. jannaschii PSTK into the pACYC-Duet vector
were described previously.5 The human wild-type and
mutant SepSecS were transformed into the E. coli DselA
strain with the M. jannaschii PSTK. Aerobic overnight
cultures were streaked on LB-agar plates supplemented
with 0.01 mM isopropyl b-D-1-thiogalactopyranoside, 1
mMNa2MoO4, and 1 mMNa2SeO3 as described previously.
7
The cells were grown anaerobically for 20 hr at 37C. The
plates were then overlaid with agar containing 1 mg/ml
benzyl viologen, 0.25 M sodium formate, and 25 mM
KH2PO4 (pH 7.0). The appearance of a blue or purple color
is the indication of active formate dehydrogenase H. It
should be noted that the addition of high selenite levels
(up to 0.1 mM) to the medium did not alter the result
(data not shown). In vitro assays could not be performed
because the SepSecS mutant proteins proved to be insol-
uble after expression.8, 2010
Figure 3. SepSecS Mutations in PCCA
Families
(A–C) The c.1001A>G SepSecSmutation in
exon 8. Sequence analysis is shown for an
affected individual (A), a carrier (B), and
an unaffected individual (C) in families A
and B.
(D and E) The c.715G>Amutation in exon
6. Sequence analysis is shown for a carrier
(D) and unaffected individuals (E) in fami-
lies C and D. Affected individuals in fami-
lies C and D were compound heterozygous
for the two mutations.
The arrows indicate the positions of the
mutations.The human SepSecS protein catalyzes the final step in
the biosynthesis of the 21st genetically encoded amino
acid, selenocysteine.5,6 Sec is the major form of the essen-
tial micronutrient selenium in the human body. Although
chemically similar to cysteine, Sec is ionized at physiolog-
ical pH and is thus more reactive. Hence, in Sec-containing
enzymes (or selenoenzymes), Sec is an essential compo-
nent of the active site.9 The codon for Sec is UGA, which
serves as a stop codon in nonselenoprotein mRNAs. The
presence of a conserved stem-loop structure in theFigure 4. Alignment of the Mutated Sequence Regions in Some Eukaryotic and Archaeal
The American Journal of Human Ge30-untranslated region of mammalian
selenoprotein mRNAs directs recod-
ing of UGA from stop to Sec in the
translating ribosome.10 The human
selenoproteome comprises 25 mem-
bers, whose biological functions
have been implicated in diverse
human diseases ranging from cardio-
vascular and endocrine disorders to
abnormalities in immune responses
and cancer.11 Five human glutathione
peroxidases (GPxs) and three thiore-
doxin reductases (TrxRs) are sele-
noenzymes that orchestrate the
human antioxidant defense mecha-nisms.9 They protect the cell from reactive oxygen species
such as hydrogen peroxide and lipid hydroperoxides and
are responsible for recycling nutritional antioxidants,
such as vitamin C, vitamin E, and coenzyme Q, as well.
Sec is also the catalytic residue in three iodothyronine de-
iodinases, the enzymes that potentiate circulating
thyroxine (T4) by converting it to its active cellular form,
triiodothyronine (T3), in peripheral tissues.9 Mutation of
the active-site Sec residue to Cys is detrimental for the cata-
lytic activity of selenoenzymes.12,13SepSecS Proteins
netics 87, 538–544, October 8, 2010 541
Figure 5. Functional Studies of the SepSecS Mutations
In vivo assays of human SepSecS mutants. Formation of Sec-
tRNASec in vivo is assayed by the ability of the wild-type human
SepSecS and the mutant variants p.Lys284Thr, p,Ala239Thr, and
p.Tyr334Cys to restore the benzyl-viologen-reducing activity of
the selenoprotein FDHH in the E. coli DselA deletion strain. The
Methanocaldococcus jannaschii PSTK is cotransformed to generate
the Sep-tRNASec intermediate. K284T is a previously described
inactive SepSecS mutant.The pathway to Sec biosynthesis in humans has recently
been deciphered,5 and the structure of the human SepSecS
in complex with the tRNAmolecule that delivers Sec to the
translating ribosome, tRNASec, has provided key insights
into the reaction mechanism.6 Biosynthetic pathways
starting from glycolysis or Krebs-cycle metabolic interme-
diates establish free cellular pools for all twenty standard
amino acids. Sec is the sole exception to this paradigm; it
is only made attached to tRNASec in three enzymatic steps
(Figure 6). Seryl-tRNA synthetase (SerRS) acylates serine
to tRNASec, and the resulting Ser-tRNASec is convertedFigure 6. Structure of Selenocysteine and Its Route of Biosynthesi
Seryl-tRNA synthetase attaches serine to tRNASec.
(Top) Bacteria use selenocysteine synthase (SelA) to convert Ser-tRNA
(Bottom) Eukaryotes and archaea employ a two-step conversion; a kin
the required substrate of SepSecS (see text).
542 The American Journal of Human Genetics 87, 538–544, Octoberby O-phosphoseryl-tRNA kinase to Sep-tRNASec. In the
presence of the cofactor pyridoxal phosphate and the sele-
nium donor selenophosphate, SepSecS then converts Sep-
tRNASec to Sec-tRNASec.
On the basis of our knowledge of SepSecS structure and
function,6,14 we expected the two founder mutations
seen in Jews of Iraqi and Moroccan ancestry to disrupt
folding and, thus, the catalytic function of the human Sep-
SecS protein. In particular, introduction of Thr in place of
Ala239 introduces steric clashes that disrupt interactions
between two helices in the enzyme’s core. Moreover,
a Cys residue instead of Tyr in position 334 would disturb
the architecture of the active site and the position of the
catalytically essential pyridoxal phosphate. Indeed, these
two mutations abrogate SepSecS activity in vivo and
disrupt the sole route to Sec biosynthesis in humans and
thus, the generation of selenoenzymes.
In contrast with the lethal phenotype of tRNASec-null
mutant mice,15 affected humans with SepSecS mutations
survive.This is concordantwithmanyexamplesofdifferent
severity of phenotypes inmice andhumans, and it iswell in
line with the human phenotype of PCH2, stemming from
a defect in another tRNA. The progressive brain atrophy
caused by the p.Ala239Thr and p.Tyr334Cys SepSecSmuta-
tions in affected individuals is in line with the known
crucial role of selenium and selenoproteins in brain devel-
opment and function. Compared to that of other organs,
the selenium content of the brain is not particularly
high.16 Nevertheless, under dietary selenium deficiency,
circulating selenoprotein P (SelP) ensures the preferential
transport of selenium reserves to the brain at the expense
of other organs.17 It is thus crucial that selenium brain
content remain stable.17,18 Indeed, knockout of SelP19 or
its brain receptor ApoER220 leads to cerebral selenium defi-
ciency and neurodegeneration phenotypes, such as ataxia
and seizures, in mice.21,22 Moreover, neuron-specific dele-
tion of tRNASec ablated expression of all 24 selenoproteins
present in themouse brain and resulted in a neurodevelop-
mental and degenerative phenotype of astrogliosis in the
cerebral cortex, cerebellum, and hippocampus.15s
Sec directly to Sec-tRNASec.
ase (PSTK) provides the phosphorylated intermediate Sep-tRNASec,
8, 2010
Healthy expression of selenoproteins is, thus, crucial for
neuronal function.23 The cerebral and cerebellar neurode-
generation in mouse models of defective neuronal seleno-
protein expression strengthens the notion that the PCCA
phenotype caused by SepSecS mutations is the result of dis-
rupted selenoprotein biosynthesis in the brain of affected
individuals. It remains to be seen which selenoproteins are
most crucial in the disease mechanism. Attempts at
delaying the clinical progression of the PCCA phenotype
with dietary selenium supplementation can be made,
althoughour invitro experiments suggest that this approach
might be futile. Moreover, because selenocysteine is gener-
ated on its cognate tRNA, selenocysteine supplementation
might also not be effective. Other, more complex strategies,
circumventing the SepSecS defect, are being sought.Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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